Skye Bioscience Signs Arrangement Agreement With Emerald Health Therapeutics, Here Are The Details
Skye Bioscience Signs Arrangement Agreement With Emerald Health Therapeutics, Here Are The Details
Skye Bioscience與Emerald Health Treateutics簽署安排協議,詳情如下
Skye Bioscience, Inc. (OTCQB:SKYE) and Emerald Health Therapeutics, Inc. (OTCQB:EMHTF) (CSE:EMH) have entered into a definitive agreement with respect to a transaction to be completed by way of a plan of arrangement whereby Skye would acquire all of the issued and outstanding shares of Emerald in a share-for-share-transaction.
斯凱生物科學公司。(OTCQB:Skye)和Emerald Health Treateutics,Inc.。(場外交易代碼:EMHTF)(CSE:EMH)已經達成了一項最終協議關於以安排計劃的方式完成的交易據此,Skye將收購Emerald的所有已發行和流通股在以股換股的交易中。
Skye is a San Diego-based pharmaceutical company developing proprietary, synthetic cannabinoid derivatives to treat glaucoma and other diseases with significant unmet needs. Emerald possesses cash and non-cash assets that Skye would acquire through the arrangement. The proposed arrangement is subject to approval by each...
斯凱是一家總部位於聖地亞哥的製藥公司開發專有的合成大麻素衍生物,用於治療青光眼和其他有重大未...
登入免費觀看全文
登入/註冊